NICE lifts restrictions on myeloma treatment teclistamab in final draft guidance The updated guidance recommends the monoclonal antibody for anyone with relapsed or refractory multiple myeloma who has received three or more lines of treatment and whose myeloma has progressed.…
CAR-T infusions delivered to ‘more than 80’ patients in Wales, says NHS Wales The NHS Wales Joint Commissioning Committee has enabled 100 patients in Wales to receive an advanced therapy medicinal product to date.…
Pharmacy teams identify patients with ‘red-flag’ cancer symptoms in early diagnosis project Exclusive: Of those identified, 17 people presenting with red-flag symptoms received a formal consultation with a pharmacist during the six-month project.…
Cancer Research UK offers training to Tesco pharmacists to spot possible cancer symptoms Tesco pharmacists have also been trained to offer advice by the British Heart Foundation and Diabetes UK.…
How can pharmacists best support patients with chronic lymphocytic leukaemia? As therapies for chronic lymphocytic leukaemia have evolved, so has pharmacists’ role in treating people with this type of blood cancer.… Supported content
MHRA approves capivasertib for treatment of advanced breast cancer Capivasertib is an oral pill given with fulvestrant, a hormonal therapy, as an alternative treatment to endocrine-based regimens.…
Draft NICE guidance recommends ‘at-home’ pill for advance prostate cancer The National institute of Health and Care Excellence says up to 40,000 people in England could benefit from relugolix (Orgovyx; Accord).…
How AI is transforming drug discovery Pharmaceutical companies and start-ups are harnessing AI to improve speed and reduce costs at every stage of the drug discovery and development process.…
Lung cancer: screening, diagnosis and management An overview of the symptoms of suspected lung cancer, treatment strategies and current national screening programmes and pilots.…
Combination treatment before surgery improves melanoma survival rates, study results show The 12-month event-free survival rate for patients with macroscopic stage III node-positive melanoma was 83.7% with the combination treatment, compared with 57.2% for adjuvant therapy alone.…
